Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Excessive Daytime Sleepiness Market Value Growth And Long-Term Outlook
The market for excessive daytime sleepiness has demonstrated significant expansion over the past few years. Projections indicate that it is set to expand from $5.39 billion in 2025 to $5.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this historical growth include the growing incidence of sleep disorders, increased recognition of how sleep health affects overall well-being, the expansion of sleep clinic infrastructure, the availability of pharmacological wake-promoting agents, and the broader provision of diagnostic sleep testing services.
The excessive daytime sleepiness market size is projected to experience robust growth in the coming years. It is anticipated to expand to $8.52 billion in 2030, achieving a compound annual growth rate (CAGR) of 9.6%. This expected growth throughout the forecast period stems from factors such as increasing demand for personalized sleep treatment plans, rising integration of digital therapeutics in sleep care, broader adoption of remote patient monitoring, a growing focus on preventive sleep healthcare, and increased investment in sleep medicine research. Key trends identified for the forecast period include the increasing uptake of wearable sleep monitoring devices, growing utilization of combination therapy approaches, expansion of home-based sleep disorder management, a rising emphasis on early diagnosis and screening programs, and enhanced integration of digital sleep health platforms.
Get A Free Sample Report With In-Depth Market Insights:
Excessive Daytime Sleepiness Market Development Factors: What’s Supporting Demand?
The growing incidence of obstructive sleep apnea (OSA) is projected to boost the excessive daytime sleepiness (EDS) market moving forward. Obstructive sleep apnea is a sleep condition defined by recurring pauses in breathing during sleep, resulting from upper airway blockage, which leads to fragmented and lower quality sleep. The rise in obstructive sleep apnea’s occurrence is linked to increasing obesity rates, as excess fat in the neck and throat narrows the airway, causing breathing disruptions during sleep. Excessive daytime sleepiness serves as a widespread and debilitating symptom of obstructive sleep apnea, often persisting in a substantial number of patients, thus creating a demand for focused therapeutic and management strategies. For instance, in August 2026, according to the National Library of Medicine, a US-based medical library, by 2050, approximately 76.6 million adults aged 30–69 in the United States are expected to be affected by obstructive sleep apnea. This increasing prevalence of obstructive sleep apnea is consequently propelling the growth of the excessive daytime sleepiness market.
Excessive Daytime Sleepiness Market Segment Trends And Revenue Contributors
The excessive daytime sleepiness market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatment; Behavioral Therapy; Continuous Positive Airway Pressure Therapy; Lifestyle Modification Programs; Combination Therapies
2) By Diagnosis Method: Polysomnography; Multiple Sleep Latency Test; Actigraphy; Clinical Evaluation; Questionnaire Based Assessments
3) By Type Of Disorder: Narcolepsy; Obstructive Sleep Apnea; Insomnia; Circadian Rhythm Disorders; Idiopathic Hypersomnia; Restless Legs Syndrome; Other Type Of Disorders
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Sleep Clinics; Ambulatory Surgical Centers; Home Care Settings
Subsegments:
1) By Pharmacological Treatment: Wake Promoting Medications; Central Nervous System Stimulant Medications; Dopamine Reuptake Inhibitor Medications; Histamine Receptor Modulating Medications
2) By Behavioral Therapy: Cognitive Behavioral Therapy For Sleep; Sleep Hygiene Education Programs; Stimulus Control Therapy; Sleep Restriction Therapy
3) By Continuous Positive Airway Pressure Therapy: Fixed Pressure Airway Therapy; Auto Adjusting Airway Therapy; Bilevel Airway Therapy; Adaptive Pressure Support Therapy
4) By Lifestyle Modification Programs: Sleep Schedule Regulation Programs; Diet And Nutrition Management Programs; Physical Activity And Exercise Programs; Stress Management And Relaxation Programs
5) By Combination Therapies: Medication And Behavioral Therapy Combinations; Airway Therapy And Lifestyle Modification Combinations; Medication And Airway Therapy Combinations; Integrated Multimodal Treatment Approaches
Excessive Daytime Sleepiness Market Transformation Trends: What Innovations Are Driving Change?
Companies operating within the excessive daytime sleepiness market are primarily focused on developing innovative solutions, including central nervous system depressants, to improve wakefulness and enhance patients’ quality of life. A central nervous system depressant is characterized as a substance that reduces nervous system activity, thereby inducing sedation, calmness, or sleep. As an illustration, in September 2025, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, obtained approval from the FDA for its sodium oxybate oral solution, which directly targets excessive daytime sleepiness (EDS) in narcolepsy patients. This innovation is designed to improve treatment continuity by enabling virtual specialist consultations, remote prescription fulfillment, and increasing patient reach in underserved regions, with the ultimate aim of expanding access, enhancing affordability, and integrating established pharmacotherapy with evolving digital and telehealth-driven care models for excessive daytime sleepiness.
Excessive Daytime Sleepiness Market Industry Leaders And Competitive Landscape
Major companies operating in the excessive daytime sleepiness market are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cleveland Clinic, EisAI Co. Ltd, Jazz Pharmaceuticals plc., Emory Healthcare Inc., Alkermes plc., Fisher & Paykel Healthcare Corporation Limited, Harmony Biosciences Holdings Inc., Medanta, Axsome Therapeutics Inc., Compumedics Limited, BIOPROJET, Apnimed Inc., Nox Health Inc., Somnogen Canada Inc., Suven Life Sciences Limited, Theranexus, XWPharma, NLS Pharmaceutics AG.
View The Full Excessive Daytime Sleepiness Market Report:
Excessive Daytime Sleepiness Market Regional Analysis And Leading Geography
North America was the largest region in the excessive daytime sleepiness market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the excessive daytime sleepiness market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
